

# Fluorescent Human GPRC5D Full Length Protein (VLP)

Catalog # GPD-HF2P7



BIOSYSTEMS  
**Acro**

Surprise Inside!

## Application

- Immunization
- Cell based assay ([FACS](#) or functional assay)
- Screening ([ELISA](#))

## Synonym

GPRC5D, G-protein coupled receptor family C group 5 member D

## Source

Fluorescent Human GPRC5D Full Length Protein-VLP (GPD-HF2P7) is expressed from human 293 cells (HEK293). It contains AA Tyr 2 - Cys 300 (Accession # [Q9NZD1-2](#)).


Predicted N-terminus: Met

## Molecular Characterization

This protein carries a GFP tag.


\*The isotype control of empty/mock VLP (Cat. No. [VLP-NF2P4](#)) is sold separately and not included in protein, you can follow [the link](#) for product information.

### • Structure



Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

### • Synthesis Process



Envelope virus-like particles (eVLPs) are produced by **co-expressing target membrane proteins with viral structural proteins in mammalian cells**, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and **strong immunogenicity** making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

## Conjugate

GFP

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm

Emission Wavelength: 530 nm

## Purity

>95% as determined by SEC-HPLC.

## Formulation

**The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).**

Supplied as 0.2  $\mu$ m filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

## Shipping

This product is supplied and shipped with dry ice, please inquire the shipping cost.

## Storage

Please protect from light and avoid repeated freeze-thaw cycles.


This product is stable after storage at:

- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.

## ACRO Quality Management System


- [QMS\(ISO, GMP\)](#)
- [Quality Advantages](#)
- [Quality Control Process](#)

## SEC-HPLC




The purity of Fluorescent Human GPRC5D Full Length Protein-VLP (Cat. No. GPD-HF2P7) was greater than 95% as determined by SEC-HPLC.

## Bioactivity-ELISA




Immobilized Fluorescent Human GPRC5D Full Length Protein-VLP (Cat. No. GPD-HF2P7) at 1 µg/mL (100 µL/well) can bind Anti-GPRC5D Antibody, Human IgG4 with a linear range of 0.002-0.313 µg/mL (QC tested).

## Bioactivity-FACS



2e5 of Anti-GPRC5D CAR-293 Cells were stained with 100  $\mu$ L of 10  $\mu$ g/mL of Fluorescent Human GPRC5D Full Length Protein (VLP) (Cat. No. GPD-HF2P7) and isotype control protein respectively. GFP signal was used to evaluate the binding activity (QC tested).

## Identity-DLS



The mean peak Radius of VLP is 65-85 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

## Background

An orphan G protein-coupled receptor with highly restricted expression in malignant plasma cells and hard keratinized tissues (hair/nail). This profile mitigates off-tumor toxicity, establishing GPRC5D as a breakthrough target for bispecific antibodies and CAR-T therapies in relapsed/refractory multiple myeloma.

Discounts, Gifts,  
and more!



[www.acrobiosystems.com](http://www.acrobiosystems.com)



6/18/2026